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Background: Liposomal cisplatin is a new formulation developed to reduce the systemic toxicity of cisplatin while
simultaneously improving the targeting of the drug to the primary tumor and to metastases by increasing circulation
time in the body ﬂuids and tissues. The primary objectives were to determine nephrotoxicity, gastrointestinal side-
effects, peripheral neuropathy and hematological toxicity and secondary objectives were to determine the response
rate, time to tumor progression (TTP) and survival.
Patients and methods: Two hundred and thirty-six chemotherapy-naive patients with inoperable non-small-cell
lung cancer were randomly allocated to receive either 200 mg/m
2 of liposomal cisplatin and 135 mg/m
2 paclitaxel
(arm A) or 75 mg/m
2 cisplatin and 135 mg/m
2 paclitaxel (arm B), once every 2 weeks on an outpatient basis.
Two hundred and twenty-nine patients were assessable for toxicity, response rate and survival. Nine treatment cycles
were planned.
Results: Arm A patients showed statistically signiﬁcant lower nephrotoxicity, grade 3 and 4 leucopenia, grade 2 and 3
neuropathy, nausea, vomiting and fatigue. There was no signiﬁcant difference in median and overall survival and TTP
between the two arms; median survival was 9 and 10 months in arms A and B, respectively, and TTP was 6.5 and 6
months in arms A and B, respectively.
Conclusions: Liposomal cisplatin in combination with paclitaxel has been shown to be much less toxic than the
original cisplatin combined with paclitaxel. Nephrotoxicity in particular was negligible after liposomal cisplatin
administration. TTP and survival were similar in both treatment arms.
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introduction
For three decades now, cisplatin has been a basic cytotoxic
agent used for the treatment of stage III and IV non-small-cell
lung cancer (NSCLC). Cisplatin-based doublet chemotherapy
consisting of docetaxel, paclitaxel, gemcitabine or vinorelbine
combinations is commonly administered as ﬁrst-line treatment
of NSCLC [1, 2]. Carboplatin is often used instead of cisplatin
in the combination [3]. The adoption of cisplatin provided
a survival advantage and a higher response rate since the start
of its use; however, its major problem has been mainly
nephrotoxicity [3]. A main substitute agent is the analogue
carboplatin [4, 5] but also other combined agents including
taxanes (paclitaxel, docetaxel) or gemcitabine, vinorelbine,
pemetrexed and irinotecan have been used [6–14]. Liposomal
cisplatin (Lipoplatin; Regulon Inc., Mountain View, CA) is
formed from cisplatin and liposomes composed of dipalmitoyl
phosphatidyl glycerol, soy phosphatidyl choline (SPC-3),
cholesterol and methoxypolyethylene glycol-distearoyl
phosphatidylethanolamine (mPEG2000-DSPE). Lipoplatin was
developed in order to reduce the systemic toxicity of cisplatin.
Preclinical studies have shown lipoplatin’s lower nephrotoxicity
in rats when compared with cisplatin [15]. Lipoplatin showed
reduced renal toxicity in mice and rats, whereas animals
injected with cisplatin developed renal insufﬁciency with clear
evidence of tubular damage [16]. Two phase I studies have
tested lipoplatin’s pharmacokinetic proﬁle and adverse
reactions [17] and preferential tumor uptake of this agent in
human studies [18]. Lipoplatin has been administered in 1 l 5%
dextrose by an 8-h infusion. The highest plasma concentration
was detected at 8 h and the platinum levels dropped to normal
after 4–7 days [17]. Lipoplatin was ‘tested’ in combination with
gemcitabine in a phase I–II trial of advanced pancreatic cancer
where doses higher than 100–150 mg/m
2 of lipoplatin were well
tolerated [19]. Other trials have shown low or negligible
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20]. The dose of lipoplatin administered alone is tolerated even
at the level of 350 mg/m
2 (G.P. Stathopoulos, S.K. Rigatos,
J. Stathopoulos, in press). The present study was designed to
compare the toxicity, effectiveness and survival of patients
ineligible for resection with NSCLC. The primary objectives
were to determine nephrotoxicity, gastrointestinal (GI) side-
effects, peripheral neuropathy and hematological toxicity and
secondary objectives were to determine the response rate, time
to tumor progression (TTP) and survival.
patients and methods
patients’ eligibility
Eligibility for the study required chemotherapy-naive patients with
histologically or cytologically conﬁrmed NSCLC; patients were to be
classiﬁed as stage IIIb and IV, or stage IIIa not amenable to curative
treatment (surgery), and to have bidimensionally measurable disease on
physical examination, X-rays, computed tomography (CT), Eastern
Cooperative Oncology Group (ECOG) performance status (PS) of zero to
two, expected survival ‡12 weeks, adequate bone marrow reserves
(leukocyte count ‡ 3500/ll, platelet count ‡ 100 000/ll and hemoglobin ‡
10 g/ll), adequate renal function (serum creatinine £ 1.5 mg/dl) and liver
function (serum bilirubin £ 1.5 mg/dl and serum transaminases £three
times the upper limit of normal or £ﬁve times the upper limit of normal in
cases of liver metastases), and age ‡ 18 years. In cases of central nervous
system involvement, patients were excluded unless they were asymptomatic.
Patients with a second malignancy were also excluded.
The study was conducted in accordance with the Declaration of Helsinki
and Good Clinical Practice Guidelines [21] and was approved by both
participating institutional ethics review boards. All patients gave their
informed consent before entering the study.
study design
The study was designed as a multicenter phase III trial by the institutional
boards of the seven participating clinics of two hospitals. The study was
powered at 80% to detect a difference in nephrotoxicity as well as in other
side-effects, such as GI (nausea–vomiting), neurotoxicity and asthenia. The
sample size was initially planned to include 100 patients in each arm with
an increase in the number of patients if a statistical difference of 5%
between the two arms, with regard to toxicity, was not reached. The
randomization was carried out centrally and patients were stratiﬁed by
three prognostic variables: disease stage (locally advanced versus
metastatic), PS (ECOG 0–2) and investigational site.
treatment plan
Patients were randomly assigned to arm A or arm B. Arm A patients were to
be treated with lipoplatin 200 mg/m
2 in combination with paclitaxel 135
mg/m
2. Lipoplatin was infused in 1 l 5% dextrose for 8 h without an extra
infusion for hydration. Paclitaxel, which was given before lipoplatin, was
infused for 3 h. Arm B patients were also given paclitaxel 135 mg/m
2 for 3 h
and cisplatin 75 mg/m
2 in 250 mg normal saline solution accompanied by
1 l 5% dextrose and 1 l electrolyte, the same day. Premedication included
ondasetron 8 mg i.v., dexamethasone 8 mg i.v. and diphenyldramine
hydrochloride 50 mg i.v. with modiﬁed timing 1 h before the beginning of
treatment and repeated 4 and 8 h thereafter. Treatment of both arms was
repeated every 2 weeks; the every 2-week treatment repetition has been
tested in other trials [8, 22–24]. Nine cycles were planned. By repeating the
treatment every 2 weeks instead of every 3 weeks, the doses of cisplatin and
paclitaxel were reduced to 75 mg/m
2 instead of 100 mg/m
2 [24] for the
former and 135 mg/m
2 instead of 175 mg/m
2 for the latter. Patients who
responded to treatment continued to the end of the planned number of
courses. Course delays of 1 week were permitted for recovery from adverse
events. Concomitant supportive therapies, such as granulocyte colony-
stimulating factors or blood transfusions, antibiotics and erythropoietic
agents were allowed according to the American Society of Clinical
Oncology guidelines [25].
baseline and treatment assessment and evaluation
Before study entry, all patients underwent the following evaluations:
medical history, physical examination, tumor measurement or evaluation,
ECOG PS, electrocardiogram, full blood count, liver and kidney function
tests, ‘serum creatinine’, ‘creatinine clearance’ and urinalysis. Staging was
determined by chest and abdominal CT, bone scan and occasionally
magnetic resonance imaging. Blood count, blood urea and serum creatinine
were measured before each treatment administration and 7 days after each
course. In cases where patients had serum creatinine levels higher than
normal, creatinine clearance was carried out. Patients with abnormal
creatinine clearance were excluded from the study. The glomerular
ﬁltration rate, type Cockroft–Gault, was not determined at baseline or
during the trial. During the treatment period, radiologic tests were
conducted after four courses, at the end of the study and after any course if
the clinical signs were indicative of disease progression. Disease status was
assessed according to the RECIST [26].
Randomly assigned patients who met the eligibility criteria and who had
baseline data were considered assessable for tumor response and duration
of response. All patients in both arms who received at least one dose
(course) of treatment were considered assessable for safety. Patients were
assessed for toxicity according to the National Cancer Institute—Common
Toxicity Criteria, version 2.0 [27]. A complete response (CR) was
considered to be the disappearance of all measurable disease conﬁrmed at 4
weeks at the earliest; a partial response (PR), a 30% decrease in all
measurable disease, also conﬁrmed at 4 weeks at the earliest. In stable
disease (SD), neither the PR nor the progressive disease (PD) criteria were
met; PD was considered to be a 20% increase of tumor burden and no CR,
PR, or SD documented before increased disease. A two-step deterioration
in PS, a >10% loss of pretreatment weight or increasing symptoms did
not by themselves constitute progression of the disease; however, the
appearance of these complaints was followed by a new evaluation of the
extent of the disease. All responses had to be maintained for at least 4 weeks
and be conﬁrmed by an independent panel of radiologists and oncologists.
statistical analysis
The main end point for sample-size determination was toxicity
[myelotoxicity, nephrotoxicity, neurotoxicity, GI side-effects and asthenia].
In order to detect a 6difference at a 3-year time point, 200 patients were
needed in order to have 80% power at the 5% signiﬁcance level.
Patients were randomly assigned to the two treatment arms: A, lipoplatin
plus paclitaxel and B, cisplatin plus paclitaxel. Randomization was carried
out according to the method of random permuted blocks within strata.
The stratiﬁcation factor comprised stages IIIa, IIIb and IV. Dynamic
balancing by center was also carried out. For time to disease progression
and overall survival (OS), the Kaplan–Meier method was used to estimate
survival distribution and the log-rank test for the comparison of the
treatment arms. An interim analysis on the basis of the O’Brien–Flemming
boundary values was carried out when 50% of the end point (100 deaths)
was reached.
For response rates and the presence of toxic effects, comparisons of the
two treatment arms were done by the v
2 test or the Fisher’s exact test, when
appropriate. The Mann–Whitney U test was used for toxicity grade
comparisons. All tests were two sided. A P value <0.05 (Pearson’s chi-
square test) was considered signiﬁcant. The duration of response was
calculated from the day of the ﬁrst demonstration of response until PD.
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PD. OS was calculated from the day of enrollment until death, or to the end
of the study.
results
From April 2006 until September 2008, a total of 236 patients
were enrolled in this multicenter trial. Two hundred and
twenty-nine patients were assessable for toxicity, response and
survival. Seven patients refused to undergo the treatment. One
hundred and fourteen patients in arm A and 115 in arm B were
assessable for safety and efﬁcacy. The patients’ characteristics
are shown in Table 1. In this table, gender, age, PS and
histological tumor differentiation are analytically presented for
both arms. The great majority of patients were stage IIIb and IV
(102 arm A: 41 stage IIIb and 61 stage IV and 100 arm B: 43
stage IIIb and 57 stage IV). Twelve patients from Arm A and 15
from Arm B of stage IIIa were considered to be ineligible for
resection due to: (a) respiratory insufﬁciency, (b) stage IIIaN2
inoperable, conﬁrmed by mediastinoscopy.
safety
Tables 2 and 3 show toxicity/statistical differences and toxicity
by grade, respectively. A difference that was statistically
signiﬁcant was temporary nephrotoxicity or its buildup over
the number of cycles. Nephrotoxicity in arm A patients treated
with lipoplatin–paclitaxel was 6.1%, while for arm B patients
treated with cisplatin–paclitaxel, it was 40.0%, P value < 0.001.
Some arm A patients had increased blood urea and serum
creatinine but this was temporary and these patients eventually
received the full nine cycles. Other side-effects with
a statistically signiﬁcant difference occurred in arm B where GI
tract nausea, vomiting and fatigue were worse than in arm A.
Myelotoxicity was higher in arm B patients and the difference
was statistically signiﬁcant for grade 3–4 neutropenia. Six
patients in arm A and 10 in arm B were hospitalized due to
febrile neutropenia. Anemia was common: 43.9% in arm A and
54.9% in arm B. Grades 1–4 leucopenia were 33.3% and 45.2%
in arm A and B patients, respectively; grades 3 and 4 leucopenia
were 12.3% and 2.6%, respectively, in arm A and 18.3% and
8.7%, respectively, in arm B (Table 2; statistically signiﬁcant
difference P value 0.017). Asthenia was more common in arm B
patients (71.3% versus 57% in arm A, P value 0.019). The side-
effect comparison was carried out for 229 patients in total.
compliance with treatment
For the response rate, 229 (114 arm A and 115 arm B) patients
were evaluated. A total of 666 cycles were administered to arm
A patients and 634 to arm B. The median number of cycles was
six in both arms. The number of planned protocol cycles (nine)
was completed in 46 patients in arm A and 43 in arm B.
Treatment was delayed for 1 week due to grade 4 leucopenia in
3 (2.6%) arm A patients and in 10 (8.7%) arm B patients; these
patients received granulocyte growth factor support. Extra
hydration due to vomiting was given to 4 (3.5%) arm A
patients and to 23 (20%) arm B patients. Blood transfusion was
given during treatment to four (3.5%) patients in arm A and to
seven (6.1%) patients in arm B.
At the time of evaluation, 128 (55.9%) patient deaths
(events) had occurred: 63 (55.3%) in arm A and 65 (56.5%) in
arm B; 111 (86.7%) died due to the disease, 7 (5.5%) of a heart
attack, 5 (3.9%) due to infection, 3 (2.3%) due to pulmonary
embolism and 1 (0.78%) because of aneurysm rupture, brain
episode and bone fracture. There was no difference in the cause
of death between arm A and arm B patients. The median
follow-up was 15 months and the range was 6–33 months.
Table 1. Patient demographics and disease characteristics at baseline
Arm A,
n (%)
Arm B,
n (%)
Total,
n (%)
No. of patients treated 114 115 229
Gender
Male 104 99 203
Female 10 16 26
Age (years)
Median 65 66
Range 37–80 41–85
ECOG performance status
0 25 (21.93) 23 (20.0) 48 (20.96)
1 75 (65.79) 77 (66.96) 152 (66.38)
2 14 (12.28) 15 (13.04) 29 (12.66)
Histology (cytology)
Adenocarcinoma 43 (37.72) 44 (38.26) 87 (37.99)
Squamous cell carcinoma 33 (28.95) 36 (31.30) 69 (30.13)
Undifferentiated NSCLC
a 34 (29.82) 34 (29.57) 68 (29.69)
Large cell carcinoma 3 (2.63) 0 3 (1.31)
Squamous +
adenocarcinoma
1 (0.88) 1 (0.87) 2 (0.87)
Differentiation
Well – 3 (2.61) 3 (1.31)
Moderate 28 (24.56) 34 (29.57) 62 (27.07)
Poor–undifferentiated 85 (74.56) 78 (67.83) 163 (71.18)
Disease stage
IIIa 12 (10.53) 15 (13.04) 27 (11.79)
IIIb 41 (35.96) 43 (37.39) 84 (36.68)
IV 61 (53.51) 57 (49.57) 118 (51.53)
aNonclassiﬁed by cytology.
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small-cell lung
cancer.
Table 2. Toxicity/statistical differences
Toxicity grade
1–4
Arm A,
n (%)
Arm B,
n (%)
P value
a
Anemia 50 (43.9) 62 (54.9) 0.112
Leucopenia (neutropenia) 38 (33.3) 52 (45.2) 0.017
Thrombocytopenia 2 (1.8) 3 (2.6) 1.000
b
Nephrotoxicity (renal) 7 (6.1) 46 (40.0) <0.001
Neurotoxicity 52 (45.6) 63 (54.8) 0.145
GI toxic nausea–vomiting 37 (32.5) 52 (45.2) 0.042
GI diarrhea 2 (1.8) 3 (2.6) 1.000
b
Asthenia 65 (57.0) 82 (71.3) 0.019
Alopecia 96 (84.2) 87 (75.7) 0.134
aPearson’s chi-square test.
bFisher’s exact test.
GI, gastrointestinal.
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Of the intent-to-treat 229 patients, a response was observed in
total in 122 patients (53.3%). In arm A, there was one CR on
the basis of CT examination (0.9%). Sixty-seven patients
achieved a PR (58.8%). SD was seen in 42 (36.8%) patients and
disease progression in 4 (3.5%). In arm B, no CR was observed.
A PR was observed in 54 (47%) patients, SD in 50 (43.5%)
patients and disease progression in 11 (9.6%) (Table 4). No
statistically signiﬁcant difference was shown in the results
between arm A and arm B. During the study process, there were
two preliminary evaluations, ﬁrst at the level of 60 patients and
second at 130. These two evaluations showed a response rate
between the two arms which was close to being statistically
signiﬁcant. By increasing the number of patients to 229, the
difference with regard to response rate remained at no
statistically signiﬁcant difference.
postcontinuation therapies/second line
According to the study protocol, patients of either arm could
undergo second-line chemotherapy in case of disease
progression or recurrence. The cytotoxic agents administered
were a combination of pemetrexed and docetaxel. Twelve
(10.5%) and 10 (8.7%) arm A and B patients, respectively, were
given the above combination with the number of cycles ranging
from two to six. The outcome was SD in all patients of both
arms. Radiation therapy was also administered to a small
percentage of patients: eight arm A patients underwent
radiotherapy for brain or bone metastasis and one for the
primary site of the disease. Eight arm B patients underwent
radiotherapy, six for brain or bone metastasis and two for the
primary site of the disease. Two patients achieved a PR.
In two patients (one in each arm, stage IIIa and IIIb), after
a PR, the disease was considered operable and a successful
operation was carried out.
The fact that a small equal number of patients in each arm had
second-line treatment and no response was observed shows that
the second-line treatment did not inﬂuence the survival data.
Two patients, one in each arm, who had undergone surgery were
alive and without recurrence at the end of the study.
survival data
The median survival of patients of arm A was 9 months [95%
conﬁdence interval (CI) 6.2–11.8]; for arm B, median survival
was 10 months (95% CI 6.8–13.2). The difference was not
statistically signiﬁcant, P value 0.577. These data are shown in
Table 4. The Kaplan–Meier survival curve is shown in Figure 1.
For arm A and B patients, median TTP was 6.5 months (95%
CI 4.7–8.3) and 6 months (95% CI 5.3–6.7), respectively, P
value 0.464. Figure 2 shows the Kaplan–Meier curve for TTP.
discussion
Liposomal cisplatin was produced to overcome the toxicity of
cisplatin, particularly nephrotoxicity. Certainly, its effectiveness
should not be inferior to cisplatin. A number of studies have
been carried out before our decision to run the present trial.
The administration of single lipoplatin has been tested to deﬁne
the dose-limiting toxicity and 350 mg/m
2 was not accompanied
by nephrotoxicity but only GI side-effects and grade 1–2
Table 3. Toxicity by grade
Arm A Arm B
Grade 1–2, n (%) Grade 3, n (%) Grade 4, n (%) Grade 1–2, n (%) Grade 3, n (%) Grade 4, n (%)
Anemia 46 (40.4) 4 (3.5) – 55 (47.8) 7 (6.1) –
Leucopenia (neutropenia
a) 21 (18.4) 14 (12.3) 3 (2.6) 21 (18.3) 21 (18.3) 10 (8.7)
Thrombocytopenia 1 (0.9) 1 (0.9) – 3 (2.6) – –
Nephrotoxicity 6 (5.3) 1 (0.9) – 40 (34.8) 5 (4.3) –
Neurotoxicity 51 (44.7) 1 (0.9) – 58 (50.4) 5 (4.3) –
Nausea–vomiting 37 (32.5) – – 51 (44.3) 1 (0.9) –
Diarrhea 2 (1.8) – – 2 (1.7) 1 (0.9) –
Asthenia 65 (57.0) – – 71 (61.7) 11 (9.6) –
Alopecia 63 (55.3) 33 (28.9) – 58 (50.4) 29 (25.2) –
aSix patients in arm A and 10 in arm B had febrile neutropenia.
Table 4. Response rate/survival time (months) (log-rank test P value
0.577)
Response rate Arm Total P value
a
AB
CR
n 101 –
% within arm 0.9 0.0 0.4 –
PR
n 67 54 121
% within arm 58.8 47.0 52.8 0.073
SD
n 42 50 92
% within arm 36.8 43.5 40.2 0.306
PD
n 41 11 5
% within arm 3.5 9.6 6.6 0.064
Total
n 114 115 229
Survival time
n 114 115 229
Median 9.0 10.0 10.0
95% CI 6.2–11.8 6.8–13.2 8.3–11.7
aPearson’s chi-square test.
CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease; CI, conﬁdence interval.
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in press). When lipoplatin is combined with another agent such
as gemcitabine, paclitaxel or 5-ﬂuorouracil (5-FU), the
maximum tolerated dose is 200 mg/m
2 (G.P. Stathopoulos,
S.K. Rigatos, J. Stathopoulos, in press). A trial in 2007
documented the combination of lipoplatin with 5-FU in
comparison with conventional cisplatin and 5-FU. This study
showed that the pharmacokinetic proﬁle of lipoplatin (in
combination with 5-FU) indicates that the liposomal
formulation results in a greater and longer body clearance,
which may conﬁrm the clinical observation of decreased
toxicity, especially renal deterioration [29]. The present study
shows that response rate, survival and TTP of patients treated
with liposomal cisplatin and paclitaxel are similar to that of
those patients treated with cisplatin and paclitaxel. However,
the important outcome is that in patients treated with
liposomal cisplatin, nephrotoxicity is negligible, as are other
adverse reactions such as nausea–vomiting, peripheral
neuropathy and asthenia, as shown by the statistical analysis.
Lipoplatin has no myelotoxicity [19] and this makes it different
from other cisplatin substitutes such as carboplatin [8].
Nephrotoxicity is negligible provided liposomal cisplatin is
infused in 1000 ml of 5% dextrose for 8 h, ‘without additional
hydration’. The median survival of the patients of both arms
was 9 and 10 months, respectively, which is similar to other
recent publications with other agent combinations in advanced
NSCLC patients [2, 4, 29–34]. The biweekly (every 2 weeks)
administration of cisplatin has also been used by other
investigators [35–38]. Cisplatin remains a fundamental agent
nowadays for the treatment of patients with advanced NSCLC.
The present trial has determined that liposomal cisplatin is not
superior in efﬁcacy to cisplatin. However, with respect to
adverse reactions, lipoplatin is much more well tolerated.
Liposomal cisplatin treatment in combination with paclitaxel
in NSCLC overcomes nephrotoxicity, the main adverse reaction
of cisplatin, while offering a similar effectiveness to cisplatin
with regard to response rate, TTP and OS.
references
1. Pﬁster DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology
treatment of unresectable non-small-cell lung cancer guidelines: update 2003.
J Clin Oncol 2004; 22: 330–353.
2. Scaglioti GV, DeMarinis F, Rinaldi M et al. for the Italian Lung Cancer Project.
Phase III randomized trial comparing three platinum-based doublets in advanced
non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285–4291.
3. Kelly K, Crowley T, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus
carboplatin versus vinorelbine plus cisplatin in the treatment of patients with
advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin
Oncol 2001; 19: 3210–3218.
4. Le Chevalier T, Scaglioti G, Natale R et al. Efﬁcacy of gemcitabine plus platinum
chemotherapy compared with other platinum containing regimens in advanced
non-small-cell lung cancer. A meta-analysis of survival outcomes. Lung Cancer
2005; 47: 69–80.
5. Non-Small-Cell Lung Cancer Collaborative Groups. Chemotherapy in non-small-
cell lung cancer: a meta-analysis using updated data on individual patients from
52 randomized clinical trials. BMJ 1995; 311: 899–909.
6. Fosella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III
study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin
for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol
2003; 21: 3016–3024.
7. Greco A, Hainsworth JD. Paclitaxel (1-h infusion) plus carboplatin in the
treatment of advanced non-small-cell lung cancer: results of a multicenter phase
II trial. Semin Oncol 1997; 24: 512–514, S12–S17.
8. Chang AY, de Vore R, Johnson D. Pilot study of vinorelbine (navelbine) and
paclitaxel in patients with refractory non-small-cell lung cancer. Semin Oncol
1996; 23: S19–S21.
9. Iaffaioli RV, Tortoriello A, Facchini G et al. Phase I–II study of gemcitabine and
carboplatin in stage IIIb–IV non-small-cell lung cancer. J Clin Oncol 1999; 17:
921–926.
10. Frasci G, Panza N, Comella P et al. Cisplatin, gemcitabine and paclitaxel in
locally advanced or metastatic non-small-cell lung cancer: a phase I–II study.
J Clin Oncol 1999; 17: 2316–2325.
11. Stathopoulos GP, Veslemes M, Georgatou N et al. Front-line paclitaxel-
vinorelbine versus paclitaxel-carboplatin in patients with advanced non-
small-cell lung cancer: a randomized phase III trial. Ann Oncol 2004; 15:
1048–1055.
12. Hanna N, Shepherd FA, Fosella FV et al. Randomized phase III trial
of pemetrexed versus docetaxel in patients with non-small-cell lung
cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:
1589–1597.
13. Giaccone G. Twenty-ﬁve years of treating advanced NSCLC: what we achieved?
Ann Oncol 2004; 15: Siv81–Siv83.
14. Dimitroulis J, Stathopoulos GP. Evolution of non-small-cell lung cancer
chemotherapy (Review). Oncol Rep 2005; 13: 923–930.
15. Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin
(Lipoplatin) in mouse xenografts. Oncol Rep 2004; 12: 3–12.
16. Devarajan P, Tarabishi R, Mishra J et al. Low renal toxicity of lipoplatin compared
to cisplatin in animals. Anticancer Res 2004; 24: 2193–2200.
0 5 10 15 20 25 30
Survival Time (months)
0.0
0.2
0.4
0.6
0.8
1.0
C
u
m
u
l
a
t
i
v
e
 
P
r
o
p
o
r
t
i
o
n
 
S
u
r
v
i
v
i
n
g
Arm
 A
 B
Figure 1. Kaplan–Meier survival curve (arm A, 95% CI 6.2–11.8; arm B,
95% CI 6.8–13.2). CI, conﬁdence interval.
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Figure 2. Kaplan–Meier TTP. TTP, time to tumor progression.
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